The MRTX Paradox: Analysts Bullish But Forecast -12.77% Fall

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Mirati Therapeutics Inc (MRTX). The average 12-month price target for MRTX — averaging the work of 7 analysts — reveals an average price target of $141.28/share..